Skip to main content

Rheumatoid Arthritis

Protocol for the pilot randomized trial of the CArdiovascular Risk assEssment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention

This open-label pilot study focuses on the peer intervention program called CArdiovascular Risk assEssment for RA (CARE RA), which provides information about the association between cardiovascular disease (CVD) and rheumatoid arthritis (RA) to patients. The study is conducted by evaluating whether patients receive a CVD risk assessment more frequently if they complete the CARE RA curriculum with a peer coach versus individually.

Read More

The development and validation of a Patient-Perceived Methotrexate Intolerance Scale for use in adult rheumatoid arthritis patients

Methotrexate is a commonly prescribed drug for patients diagnosed with rheumatoid arthritis (RA). Though it can positively impact disease activity, some patients experience side effects and intolerance. Salt et al. developed a scale to measure methotrexate intolerance for use in adult rheumatoid arthritis (RA) patients with an additional objective to describe its psychometric properties.

Read More

Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower Registry

This study aims to quantify methotrexate (MTX)-associated side effects in rheumatoid arthritis (RA) or psoriatic arthritis (PsA) patients. In the ArthritisPower app and registry, a self-controlled case series study design with electronic patient-reported outcome measures (e-PROMs) was used.

Read More

Assessing RA Disease Activity with Promis Measures Using Digital Technology

American College of Rheumatology Journals logo

In Arthritis Care & Research, Yun et al. report using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) instruments in substitution for lengthier Patient-Reported Outcomes instruments such as the Routine Assessment of Patient Index Data 3 (RAPID3). 6,154 eligible patients contributed 11,275 observations using 4 PROMIS computer-adaptive testing instruments and the RAPID3. There was excellent agreement between the observed RAPID3 and predicted RAPID3 scores estimated using several PROMIS instruments. PROMIS may be used in place of RAPID3 and other patient global assessment components.

Read More